Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 5/20 | 0.65 |
| ▸ | PIM1 | P11309 | 1/20 | 0.56 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.56 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.54 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.53 |
| ▸ | HTR3B | O95264 | 3/20 | 0.53 |
| ▸ | HTR3A | P46098 | 3/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 5/20 | 0.49 |
| ▸ | CA1 | P00915 | 5/20 | 0.49 |
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | CA9 | Q16790 | 5/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL10408560 | 0.98 | ALDH1A1 (0.96) | ALDH1A1KDM4ELMNAHTR6PIM1 | |
| SCHEMBL31531621 | 0.83 | ALDH1A1 (0.71) | ALDH1A1KDM4ELMNAHTR6ADRB1 | |
| SCHEMBL18118187 | 0.82 | LMNA (0.70) | ALDH1A1KDM4ELMNACA12CA1 | |
| SCHEMBL9097181 | 0.82 | LMNA (0.70) | ALDH1A1KDM4ELMNACA12CA1 | |
| SCHEMBL532144 | 0.81 | ALDH1A1 (0.69) | ALDH1A1KDM4ELMNAHTR6ADRB1 | |
| SCHEMBL18118191 | 0.81 | LMNA (0.68) | ALDH1A1KDM4ELMNACA12CA1 | |
| SCHEMBL8193969 | 0.81 | LMNA (0.68) | ALDH1A1KDM4ELMNACA12CA1 | |
| Hydrochloric Acid SCHEMBL20482315 | 0.80 | KDM4E (0.67) | ALDH1A1KDM4ELMNAHTR6ADRB1 | |
| Piperazine SCHEMBL27980528 | 0.80 | ALDH1A1 (0.67) | ALDH1A1KDM4ELMNAHTR6ADRB1 | |
| SCHEMBL12719397 | 0.80 | HTR6 (0.70) | ALDH1A1KDM4ELMNAHTR6ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596059-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS DUAL ATX/CA INHIBITORS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| US-11925637-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | SRX CARDIO, LLC (US) | 2024-03-12 | — | — | US | disclosed |
| US-11622970-B2 | BCL-2 inhibitors and their use as pharmaceuticals | Prelude Therapeutics Incorporation (US) | 2023-04-11 | — | — | US | disclosed |
| US-20220047582-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | SRX CARDIO, LLC | 2022-02-17 | — | — | US | disclosed |
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-11-11 | — | — | US | disclosed |
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-11-11 | — | — | US | disclosed |
| WO-2021222174-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021222174-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-11-04 | — | — | WO | disclosed |
| US-11059794-B2 | Heterocyclic compounds useful as dual ATX/CA inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-10980801-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | SRX CARDIO, LLC (US) | 2021-04-20 | — | — | US | disclosed |
| EP-0906294-A1 | BENZOXAZINONE DOPAMINE D4 RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-04-07 | — | — | EP | disclosed |
| US-5877317-A | Heterocyclic compounds for the treatment of CNS and cardiovascular disorders | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-02 | — | — | US | disclosed |
| EP-0836599-A1 | 1,6-DISUBSTITUTED ISOCHROMANS FOR TREATMENT OF MIGRAINE HEADACHES | PHARMACIA & UPJOHN COMPANY (US) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997045419-A1 | BENZOXAZINONE DOPAMINE D4 RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-12-04 | — | — | WO | disclosed |
| EP-0809642-A1 | IMIDAZO 1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1997002259-A1 | 1,6-DISUBSTITUTED ISOCHROMANS FOR TREATMENT OF MIGRAINE HEADACHES | PHARMACIA & UPJOHN COMPANY (US) | 1997-01-23 | — | — | WO | disclosed |
| CN-1139431-A | Heterocyclic compounds for the treatment of central nervous system and cardiovascular diseases | PHARMACIA & UPJOHN CO LLC (US) | 1997-01-01 | — | — | CN | disclosed |
| EP-0737189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1996025414-A1 | IMIDAZO[1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1996-08-22 | — | — | WO | disclosed |
| WO-1995018118-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | THE UPJOHN COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | BCL2, BCL2L2, BCL2L1 | ALDH1A1 3922/4885KDM4E 2431/4885LMNA 1095/4885 |
| US-11622970-B2 | BCL-2 inhibitors and their use as pharmaceuticals | BCL2, BCL2L2, BCL2L1 | ALDH1A1 3922/4885KDM4E 2431/4885LMNA 1095/4885 |
| US-20220047582-A1 | PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) MODULATORS AND THEIR USE | PCSK9, LDLR, PCSK7 | ALDH1A1 3918/4885KDM4E 1841/4885LMNA 328/4885 |
| US-10980801-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | PCSK9, LDLR, PCSK7 | ALDH1A1 3918/4885KDM4E 1841/4885LMNA 328/4885 |
| US-11925637-B2 | Phenylpiperazine proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators and their use | PCSK9, LDLR, PCSK7 | ALDH1A1 3918/4885KDM4E 1841/4885LMNA 328/4885 |
| US-11059794-B2 | Heterocyclic compounds useful as dual ATX/CA inhibitors | ATXN2, ATXN2L, ATXN10 | ALDH1A1 3727/4885KDM4E 1402/4885LMNA 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.